VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

27 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

21 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

10 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

09 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

06 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis

09 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

30 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress

10 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023

03 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

02 Aug 2023 16:06:38 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor

14 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

31 May 2023 08:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

11 May 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

04 May 2023 16:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

24 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

23 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

15 Mar 2023 16:05:01 By Nasdaq GlobeNewswire